Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07047716 · ClinicalTrials.gov registry record · Phase 3
Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)
A Phase 3 study of HIV Pre-exposure Prophylaxis, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT07047716 is a Phase 3 study of HIV Pre-exposure Prophylaxis that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 350 participants, below the 813-participant average among 7 other HIV Pre-exposure Prophylaxis trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT07047716, a Phase 3 study of HIV Pre-exposure Prophylaxis, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in people with an indication for PrEP. The primary objective of this study is to evaluate the pharmacokinetics (PK) and the safety and tolerability of intramuscular (IM) every 12 months (Q12M) LEN for PrEP among people with an indication for PrEP.
Conditions Studied
Interventions
- DRUG Lenacapavir Injection
- DRUG Lenacapavir Tablet
Study Locations (20)
California
- UCLA Clinic Care - Los Angeles
- Ruane Clinical Research Group, Inc. - Los Angeles
- UCLA Vine Street Clinic - Los Angeles
- Mills Clinical Research - Los Angeles
- BIOS Clinical Research - Palm Springs
- UCSD AntiViral Research Center (AVRC) - San Diego
- Bridge HIV, San Francisco Department of Public Health - San Francisco
Florida
- Midway Immunology and Research Center - Ft. Pierce
- The ID Prevention Research Unit - Miami
- University of South Florida - Curran Children's Health Center - Tampa
District of Columbia
- Whitman-Walker Institute, Inc. - Washington D.C.
- Children's National Hospital - Washington D.C.
Georgia
- The Hope Clinic of Emory University - Atlanta
- Ponce de Leon Center Clinical Research Site - Atlanta
Illinois
- University of Illinois-Chicago (UIC), Center for Dissemination and Implementation Sciences (CDIS) - Chicago
- Howard Brown Health Center - Chicago
Alabama
- UAB Sexual Health Research Clinic - Birmingham
Connecticut
- Yale University; School of Medicine; AIDS Program - New Haven
Louisiana
- University Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2028-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07047716
The ClinicalTrials.gov registry entry for NCT07047716 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 813-participant average among 7 other HIV Pre-exposure Prophylaxis trials with a reported enrollment target (57% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Pre-exposure Prophylaxis appearing as the primary indexed condition, and to 2 interventions - of which Lenacapavir Injection is the first listed.
NCT07047716 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT07047716 about?
NCT07047716 is a clinical study titled "Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)". The goal of this clinical study is to learn more about the study drug lenacapavir (LEN), safety, tolerability, and pharmacokinetics (how LEN is absorbed, modified, distributed, and removed from the body of the participants) of once-yearly intramuscular for HIV pre-exposure prophylaxis (PrEP) in peop...
What is the current status of trial NCT07047716?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 350 participants. The study started on 2025-07-22. Estimated completion is 2028-09.
What conditions does trial NCT07047716 study?
This clinical trial studies the following conditions: HIV Pre-exposure Prophylaxis.
What interventions are being tested in trial NCT07047716?
The interventions under investigation include: Lenacapavir Injection (DRUG), Lenacapavir Tablet (DRUG).
Who is sponsoring clinical trial NCT07047716?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07047716 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Pre-exposure Prophylaxis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
RECRUITING · Phase 3
-
Client-Centered Care Coordination for Black Men Who Have Sex With Men
RECRUITING · NA
-
Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP
RECRUITING · Phase 4
-
Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men
ACTIVE NOT RECRUITING · NA
-
A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.